Plain-English translation of NCT06195800 on ClinicalTrials.gov ↗ ·
Autologous haematopoietic stem cell transplantation (aHSCT) is a one-time treatment that resets the immune system by removing it with chemotherapy and rebuilding it using a patient's own stem cells. This study will collect blood, spinal fluid, and stool samples from people receiving this treatment and compare them to those receiving standard high-efficacy MS medications, to understand what makes the treatment work well for some patients but not others.
Although this treatment has helped over 1,800 people with MS across Europe, doctors don't yet understand exactly how it works or why some patients don't respond as well as others. There is currently no way to predict who will benefit most or to monitor the immune system after treatment to catch problems early.
You likely qualify if…
You likely don't qualify if…
You will provide biological samples (blood, fluid from around your spinal cord, and stool) at different timepoints if you are receiving stem cell transplantation or standard MS treatment. You will also complete clinical assessments during your follow-up visits. The study will compare your immune system samples to those of other participants to identify patterns that help explain why some people respond better to treatment than others.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United Kingdom